Was There Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occurring in Copenhagen

Area of Science:

• Pharmacovigilance
• Nephrology
• Dermatology

Background:

• Serious adverse drug reactions (ADRs) are frequently identified years post-FDA approval.
• Delayed identification of ADRs poses significant public health challenges.
• Nephrogenic systemic fibrosis (NSF) serves as a notable recent example of a delayed-onset ADR.

Purpose of the Study:

• To highlight the issue of delayed identification of serious adverse drug reactions.
• To discuss the specific case of nephrogenic systemic fibrosis (NSF) as an illustration.
• To underscore the importance of ongoing post-market surveillance.

Main Methods:

• Review of post-marketing surveillance data.
• Analysis of case reports and literature concerning NSF.
• Examination of the timeline of ADR identification relative to drug approval.

Main Results:

• Over 50% of serious ADRs are identified more than seven years after initial FDA approval.
• Nephrogenic systemic fibrosis (NSF) is a syndrome that developed unusually late after the implicated drug's market entry.
• The nomenclature of NSF evolved, initially termed nephrogenic dermatopathic fibrosis.

Conclusions:

• There is a critical need for enhanced post-market drug safety monitoring.
• The delayed recognition of syndromes like NSF emphasizes the limitations of pre-market drug evaluation.
• Continued vigilance is essential to detect and manage rare but severe adverse drug events.